Scottish Health Innovations Ltd
SUBMIT AN IDEA
Do you have an idea that may improve patient care? You can submit your idea on-line. Click here to find out more.
Ambulight PDT receives CE Mark approval ahead of European launch |
 Ambicare Press Release 19th October 2009 Ambulight PDT receives CE Mark approval ahead of European launch The world’s first light emitting sticking plaster for the treatment of skin cancer Ambicare, a leading developer of ambulatory light sources for medical and consumer healthcare applications today announces that it has received CE Mark approval to market its lead product, Ambulight PDT, in Europe. Photodynamic Therapy and Phototherapy are leading treatments for many skin conditions. Ambulight PDT is the world’s first skin cancer treatment using a small disposable light emitting sticking plaster (“plaster”) worn by the patient. This is used in conjunction with a prescribed pharmaceutical, for the treatment of non-melanoma skin cancer. This plaster delivers photodynamic therapy treatment (“PDT”) directly to the skin lesion site. Ambulight PDT offers healthcare providers the opportunity to transform patient care by making PDT more accessible and enabling patients to continue with their normal daily routine when undergoing PDT treatment. Pilot clinical trials have also indicated this treatment method has lower pain than conventional techniques whilst still obtaining an equivalent outcome. Current PDT treatment generally involves a day patient appointment at the hospital where a large static PDT light source is used to treat a limited number of patients. This is inconvenient for the patient and costly for the healthcare provider as it ties up a hospital day bed, as well as restricting the number of patients who can be treated. Ambulight PDT will reduce costs for the healthcare provider by freeing up these beds and improve patient care, freeing up their time to continue with their normal daily lives. In Europe PDT is the first line of treatment recommended for non melanoma skin cancer. It is a two-step process involving the application of a pharmaceutical cream which creates a photosensitive daughter compound, followed by controlled exposure to a selective light source which activates the light sensitive chemical and destroys the diseased cells. The alternative treatment methods to PDT are surgery, use of topical creams and cryotherapy. Each of these can be painful, irritate the skin, leave scarring and can be highly stressful for the patient. PDT treatment is less invasive than surgery and avoids the scarring associated with surgical removal of the lesion which can often require an in-patient hospital stay. Ambulight PDT gives healthcare providers the opportunity to shift treatment from hospitals to primary care such as GP surgeries or office based dermatologists. Ambicare also plans to use Ambulight technology in applications for the treatment of cosmetic skin conditions, including acne and anti-wrinkle. Dr Ian Muirhead, Chief Executive Officer of Ambicare said: “This is a key milestone and a significant achievement for the company. We are now actively engaging with potential partners for the distribution of this revolutionary product in Europe. We will also be taking Ambulight PDT through regulatory approvals in additional countries, such as USA and Australia. This will allow us to bring the benefits of our technology to patients in the wider global market.” For further information please contact: Ambicare Health Limited Dr Ian Muirhead ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ) 0771 498 0617 This story also appeared in the Health Investor & The Courier |
Featured Product
Multifocal Imager 3GEN
 |
 |
 |
 |
 |
 |